MedTrace Logo

Mast-Cell Stabilizing Effects of Olopatadine

NCT00389025 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-11-22

No results posted yet for this study

Summary

To assess the effects of olopatadine of the release of mast cell histamine

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Olopatadine (generic name)

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Terry Wiernas · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389025 on ClinicalTrials.gov